OBJECTIVE The objective of the study was to determine whether statin use could reduce the risk of the incidence or progression of osteoarthritis (OA). METHODS The PubMed, Embase, and Cochrane databases were systematically searched for observational studies on the association between statin use and OA. ORs and 95% CIs were directly retrieved or calculated. The Newcastle-Ottawa quality assessment scale was used for study quality assessment. Subgroup analysis, sensitivity analysis, and publication bias were conducted using Stata software. RESULTS A total of 11 studies (679807 participants) were identified from the systematic literature search. No significant association between statin use and incidence (OR = 1.010; 95% CI: 0.968 to 1.055; P = 0.638) or progression (OR = 1.076; 95% CI: 0.824 to 1.405; P = 0.589) of OA was found in our meta-analysis. The meta-analysis according to the symptomatic or radiological OA also found no significant association between statin use and OA. The subgroup analysis showed that atorvastatin (OR = 0.953; 95% CI: 0.911 to 0.998; P = 0.041) and rosuvastatin (OR = 1.180; 95% CI: 1.122 to 1.241; P < 0.0001) had opposite effects on OA. The results of the analysis according to the joint site, interval, and statin dose were all not significant. CONCLUSIONS Statin use may not be associated with a lower risk of incidence and progression of OA, regardless of joint site. The opposite effects of atorvastatin and rosuvastatin were detected in OA.

中文翻译：

---

他汀类药物的使用与骨关节炎的发生或进展之间的关联：观察性研究的荟萃分析

目的 本研究的目的是确定使用他汀类药物是否可以降低骨关节炎 (OA) 的发生率或进展风险。方法 系统地搜索 PubMed、Embase 和 Cochrane 数据库，以寻找有关他汀类药物使用与 OA 之间关联的观察性研究。直接检索或计算 OR 和 95% CI。纽卡斯尔-渥太华质量评估量表用于研究质量评估。使用Stata软件进行亚组分析、敏感性分析和发表偏倚。结果 通过系统文献检索，共确定了 11 项研究（679807 名参与者）。在我们的研究中发现他汀类药物的使用与 OA 的发生率（OR = 1.010；95% CI：0.968 至 1.055；P = 0.638）或进展（OR = 1.076；95% CI：0.824 至 1.405；P = 0.589）之间没有显着关联元分析。根据症状性或放射学 OA 的荟萃分析也发现他汀类药物的使用与 OA 之间没有显着关联。亚组分析显示，阿托伐他汀（OR = 0.953；95% CI：0.911 至 0.998；P = 0.041）和瑞舒伐他汀（OR = 1.180；95% CI：1.122 至 1.241；P < 0.0001）对 OA 具有相反的影响。根据关节部位、间隔和他汀类药物剂量的分析结果均不显着。结论无论关节部位如何，他汀类药物的使用可能与降低 OA 发生率和进展风险无关。在 OA 中检测到阿托伐他汀和瑞舒伐他汀的相反作用。041）和瑞舒伐他汀（OR = 1.180；95% CI：1.122 至 1.241；P < 0.0001）对 OA 有相反的影响。根据关节部位、间隔和他汀类药物剂量的分析结果均不显着。结论无论关节部位如何，他汀类药物的使用可能与降低 OA 发生率和进展风险无关。在 OA 中检测到阿托伐他汀和瑞舒伐他汀的相反作用。041）和瑞舒伐他汀（OR = 1.180；95% CI：1.122 至 1.241；P < 0.0001）对 OA 有相反的影响。根据关节部位、间隔和他汀类药物剂量的分析结果均不显着。结论无论关节部位如何，他汀类药物的使用可能与降低 OA 发生率和进展风险无关。在 OA 中检测到阿托伐他汀和瑞舒伐他汀的相反作用。